Merck (CGRP programme Rights) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Merck (CGRP programme Rights) General Information

Description

Migraine drugs for treatment and prevention of migraines. The receptor antagonists and oral calcitonin gene-related peptide is used for treatment of migraines.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
  • Kenilworth, NJ
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Merck (CGRP programme Rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Merck (CGRP programme Rights)‘s full profile, request access.

Request a free trial

Merck (CGRP programme Rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Merck (CGRP programme Rights)‘s full profile, request access.

Request a free trial